Treatment of Patients With Blepharitis and Facial Rosacea
NCT ID: NCT00560703
Last Updated: 2021-02-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
70 participants
INTERVENTIONAL
2007-11-30
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
NCT01355458
Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo
NCT01426269
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
NCT01355471
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
NCT01318733
Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%
NCT00697541
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COL-101 (doxycycline, USP) capsules
COL-101
COL-101 (doxycycline, USP) capsules
40mg, once per day for 84 days
Placebo
Sugar capsule
placebo
sugar capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COL-101 (doxycycline, USP) capsules
40mg, once per day for 84 days
placebo
sugar capsule
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* facial rosacea
Exclusion Criteria
* allergy to tetracyclines
* recent eye surgery
* past or current use of isotretinoin
* patients who are achlorhydric
* patients who have had gastric by-pass surgery
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Galderma R&D
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Graeber, MD
Role: STUDY_DIRECTOR
Galderma R&D
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pleasant Valley Ophthalmology
Little Rock, Arkansas, United States
Warren Scherer, MD
Naples, Florida, United States
Kentucky Lions Eye Center
Louisville, Kentucky, United States
Washington University School of Medicine
St Louis, Missouri, United States
Marguerite McDonald, MD
Lynbrook, New York, United States
Dean McGee Eye Institute
Oklahoma City, Oklahoma, United States
Anita Nevyas-Wallace, MD
Bala-Cynwyd, Pennsylvania, United States
Tanner Clinic
Layton, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COL-101-BLEPH-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.